Corpus Intelligence IC Memo — NAZARETH HOSPITAL-PHILA PA 2026-04-26 14:10 UTC
IC Memo — NAZARETH HOSPITAL-PHILA PA
Investment Committee Memorandum | PA | 152 beds | Grade D | EBITDA uplift $6.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NAZARETH HOSPITAL-PHILA PA

CCN 390204 | PHILADELPHIA, PA | 152 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

NAZARETH HOSPITAL-PHILA PA is a 152-bed under-performing / distressed in PHILADELPHIA, PA with $92.4M in net patient revenue and a -81.8% operating margin. The hospital serves a payer mix of 33.9% Medicare, 5.6% Medicaid, and 60.5% commercial.

Thesis: Undervalued. Our ML models identify $6.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -81.8% to -74.5% (+736bps).

Net Revenue HCRIS$92.4M
Current EBITDA COMPUTED$-75.6M
Operating Margin COMPUTED-81.8%
Occupancy HCRIS57.2%
Revenue / Bed COMPUTED$608K
Net-to-Gross HCRIS14.5%
Distress Probability ML46.4%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
102
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -81.8% places it below the state median. Among 102 size-comparable peers (76-304 beds), the median margin is -7.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (76-304), prioritizing same-state peers. 102 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NAZARETH HOSPITAL-PHILA PA (Target)PA152$92.4M-81.8%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
COMMUNITY MEDICAL CENTERPA266$474.1M3.1%
THE CHESTER COUNTY HOSPITALPA299$473.6M-8.9%
ROBERT PACKER HOSPITALPA252$471.8M-2.1%
WILLIAMSPORT HOSPITAL & MEDICAPA227$459.8M-8.4%
CROZER CHESTER MEDICAL CENTERPA296$459.6M-19.6%
MOUNT NITTANY MEDICAL CENTERPA248$441.7M12.6%
MEMORIAL MEDICAL CENTERPA241$435.1M-21.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.9M+210bp18mo
Cost to Collect4.5%2.5%$1.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.1M+122bp9mo
Clean Claim Rate88.0%96.0%$59K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.9M
Cost to Collect
$1.8M
Denial Rate Reduction
$1.8M
A/R Days Reduction
$1.1M
Clean Claim Rate
$59K
Total EBITDA Uplift$6.8M
Current EBITDA$-75.6M
+ RCM Uplift+$6.8M
Pro Forma EBITDA$-68.8M
Current Margin-81.8%
Pro Forma Margin-74.5%
WC Released (1x)$3.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-116.3M$-430.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-116.3M$-511.4M0.00x-100.0%
Bull Case9.0x11.0x$-104.7M$-526.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-104.7M$-605.5M0.00x-100.0%
Bear Case11.0x10.0x$-127.9M$-426.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-127.9M$-511.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 102 hospitals with 76-304 beds
  • Same-state prioritization (n=103)
  • Comp margins: P25=-18.5% / P50=-7.5% / P75=3.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.